Molecular analysis of in vivo resistance to a bcr/abl inhibitor in leukemic cells

Projektinformationen

HOLGERRUCHATZ

ID Finanzhilfevereinbarung: QLK3-CT-1999-51065

Projekt abgeschlossen

Startdatum 1 März 1999

Enddatum 28 Februar 2001

Finanziert unter

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Gesamtkosten € 130 912,00

EU-Beitrag € 130 912,00

Koordiniert durch

ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI
Italy

Ziel

The oncogenic fusion protein BCR/ABL causes human leukemia. A specific inhibitor of BCR/ABL is an effective treatment of tumors in vivo. The project aims at investigating molecular mechanisms underlying resistance to the inhibitor in vivo.

Wissenschaftliches Gebiet

• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › oncology › leukemia

Programm/Programme

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thema/Themen

• 1.1.1.-3. - Key action The "Cell factory"

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

RGI - Research grants (individual fellowships)

Koordinator

ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI

• EU-Beitrag: Keine Daten
• Adresse: Via Venezian 1 ; 20133 MILANO ; Italien
• Gesamtkosten: Keine Daten